Strategic Research Collaboration
Service · Custom development by Isomorphic Labs
Pioneering collaborations to solve all disease through AI-first drug design.
Strategic Research Collaboration is Isomorphic Labs' interdisciplinary partnership service for pharmaceutical companies to discover novel therapeutics using AI. It combines the Isomorphic Labs Drug Design Engine with deep biomedical expertise to solve challenging disease targets.
- Languages
- English
Category: Drug Discovery
- Engagement model
- Strategic research collaboration
- Industries served
- Pharmaceutical, Biotech, CRO
- Primary Modalities
- Small molecules, biologics, peptides
- Key Partners
- Novartis, Eli Lilly, Johnson & Johnson
- Focus Areas
- Target identification, molecular design, property prediction
- Strategic collaborations with Novartis, Eli Lilly, and Johnson & Johnson
- Multi-target, cross-modality research including small molecules and biologics
- Interdisciplinary teams of AI researchers and drug discovery experts
- Powered by the Isomorphic Labs Drug Design Engine (IsoDDE)
Overview
Strategic Research Collaboration is Isomorphic Labs' primary service for pharmaceutical and biotechnology companies seeking to accelerate drug discovery through AI. The company partners with industry leaders like Novartis, Eli Lilly, and Johnson & Johnson to apply its AI-first approach to identify novel molecules and develop therapeutics across various modalities, including small molecules and biologics. These engagements involve interdisciplinary teams of machine learning researchers, chemists, and biologists working side-by-side with partner organizations to solve challenging biological problems. The service leverages the Isomorphic Labs Drug Design Engine (IsoDDE) to navigate vast chemical spaces and predict molecular properties with high fidelity. By combining breakthrough technology with biomedical expertise, the collaborations aim to move potential medicines toward the clinic and ultimately to patients.
Therapeutic Development
- Small Molecule Discovery: The service applies AI-first drug design to identify novel small molecule therapeutics against challenging biological targets.
- Cross-Modality Research: Research collaborations extend across various modalities, including biologics and peptides, to address historically out-of-reach diseases.
- Novel Target Identification: The service focuses on identifying novel molecules for diseases that have historically been out of reach for traditional methods.
- Clinical Advancement: Partnerships are measured by how far they move potential medicines toward the clinic and ultimately to patients.
Engagement Model
- Interdisciplinary Teams: Isomorphic Labs machine learning researchers and engineers work side by side with partner teams throughout each program.
- Continuous Exchange: Partners share evidence and apply scientific judgement together to decide what to design, make, and test next.
- Compute-Driven Iteration: The collaboration leverages large-scale computing power to interrogate multiple hypotheses simultaneously.
- Synergy-Based Design: Each partner brings deep expertise and perspective to the work to open new routes towards potential medicines.
How it works
- Continuous exchange, sharing evidence, applying scientific judgement, deciding what to design, make and test next
Published results
- Discovery of small molecule therapeutics against challenging targets; expansion of research programs
Use cases
- Pharmaceutical companies partner with Isomorphic Labs to discover small molecule therapeutics against challenging biological targets.
- Biotech firms use the collaboration to identify novel molecules for diseases that have historically been out of reach.
- Research organizations work side-by-side with Isomorphic's AI researchers to move potential medicines toward the clinic.
Specifications
- Engagement model
- Strategic research collaboration
- Team
- Machine learning researchers, engineers, chemists, biologists, and clinicians
- Industries served
- Pharmaceutical, Biotech, CRO
- Primary Modalities
- Small molecules, biologics, peptides
- Key Partners
- Novartis, Eli Lilly, Johnson & Johnson
- Focus Areas
- Target identification, molecular design, property prediction
How it works
- Partnership Initiation: Isomorphic Labs enters into a strategic research collaboration with pharmaceutical or biotech partners to address specific disease targets.
- Collaborative Research: Interdisciplinary teams from both organizations work side by side, sharing evidence and applying scientific judgement.
- Design and Iteration: The teams use the Isomorphic Labs Drug Design Engine to design, make, and test potential medicines.
- Clinical Advancement: The collaboration aims to move potential medicines toward the clinic and ultimately to patients.
Added by AntSpace from public sources (isomorphiclabs.com).